Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
GastroEsophageal Cancer: early-phase trial registry
8 of 24 indexed GastroEsophageal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 8 currently recruiting · #686 of 28,707 conditions by registered trial count
GastroEsophageal Cancer: 24 US clinical trials tracked, 8 recruiting.
GastroEsophageal Cancer is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 3 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-cancer
OPEN 8 | RECR 33% | LATE 1 | EARLY 16 | RANK #686 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
GastroEsophageal Cancer lists 8 open slots (33% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for GastroEsophageal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
GastroEsophageal Cancer is recruiting below its size-band peers.
8 of 24 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of GastroEsophageal Cancer trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 3 of 24 trials (12.5%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most GastroEsophageal Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 24 trials that report a genuine target (sentinel values excluded). 18 of those (75%) plan for fewer than 100 participants.
-
GastroEsophageal Cancer research is mostly interventional.
20 interventional and 4 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06497569
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Harry H Yoon
NCT04069273
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Medical College of Wisconsin
NCT06906887
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06109467
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
M.D. Anderson Cancer Center
NCT05205343
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Merck Sharp & Dohme
NCT06356311
Supportive Oncology Care At Home RCT
Massachusetts General Hospital
NCT04544046
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
NCT04164979
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03044613
Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy
Ohio State University Comprehensive Cancer Center
NCT05717998
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients
H. Lee Moffitt Cancer Center and Research Institute
NCT05438940
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03610711
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
NCT05379972
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
Memorial Sloan Kettering Cancer Center
NCT06243757
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Leap Therapeutics
NCT02013154
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations
NCT01611857
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences
NCT03629756
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
NCT00673673
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
NCT03279237
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
University of Wisconsin, Madison
NCT03490292
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on GastroEsophageal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on GastroEsophageal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this GastroEsophageal Cancer page
24 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 GastroEsophageal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most GastroEsophageal Cancer trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This GastroEsophageal Cancer condition card totals 24 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.